The European Commission said on Friday it had given conditional approval for the use of antiviral remdesivir in severe COVID-19 patients following an accelerated review process, making it the region’s first therapy to be authorised to treat the virus. The move comes just a week after the European Medicines Agency (EMA) gave its go-ahead for the drug produced by Gilead Sciences to be use in adults and adolescents from 12 years of age who are also suffering from pneumonia and require oxygen support. It also comes just days after the company allocated nearly all of its supply of …read more
Source:: Yahoo Finance
